HDAC9 and soft tissue sarcoma: A regulatory network reconstruction combined with the CMAP drug data revealed not only the commonly used drug doxorubicin, but also indicated that HDAC inhibitors could be a potential treatment for many different soft tissue sarcoma subtypes.